Key result
Arbutin attenuates doxorubicin cardiotoxicity while shrinking tumors in preclinical models via inflammasome inhibition.
Why the study?
Doxorubicin causes dose- and time-dependent cardiotoxicity, and many cancer patients experience cardiovascular events; the study examined arbutin's antitumor and cardioprotective effects against cancer and doxorubicin-induced cardiotoxicity.
Does arbutin reduce tumor growth and prevent doxorubicin-induced cardiotoxicity in a Solid Ehrlich carcinoma mouse model?
Does arbutin reduce tumor growth and prevent doxorubicin-induced cardiotoxicity in a Solid Ehrlich carcinoma mouse model?
In a mouse model of solid Ehrlich carcinoma, arbutin demonstrated both antitumor efficacy and protection against doxorubicin-induced cardiotoxicity via modulation of inflammasome and oxidative stress pathways.
Answers are grounded in this paper and cite their sources.
Should not change doxorubicin regimens; hypothesis-generating for arbutin in cardio-oncology and requires human trials.
Doxorubicin (DOX) is an effective cancer therapy; however, it causes a lethal dose and time-dependent cardiotoxicity. Many patients also have cardiovascular events due to cancer itself. Therefore, our objective was to examine the antitumor effect of the natural compound arbutin and its potential cardioprotective effects against cancer and DOX-induced cardiotoxicity. Solid Ehrlich carcinoma (SEC) was established in female Swiss albino mice. DOX was administered at a dose of 6 mg/kg, ip once weekly for 21 days. A dose of 50 mg/kg ip of arbutin was administered daily for 21 consecutive days. Both tumor and heart tissues were investigated. Our results indicated that arbutin effectively reduced tumor weight and volume, both when used alone or combined with DOX, by decreasing tumor malonaldehyde and increasing glutathione levels. They also lowered tumor Sirtuin 1 (SIRT1) and increased caspase-3 expression. Unlike DOX, arbutin suppressed tumor NLR-family pyrin domain containing 3 (NLRP3), NIMA-related kinase 7 (NEK7), caspase 1, and interleukin-1-beta (IL-1β) expressions. Moreover, arbutin reduced high cardiac marker levels and attenuated cardiotoxicity by decreasing the cardiac NLRP3, NEK7, caspases 1 and 3, and IL-1β, and increasing SIRT1 expressions. Therefore, arbutin may represent a promising antitumor drug or an adjuvant therapy in the SEC model to mitigate possible cardiac issues.
No takes yet. Share an insight, caveat, or question.
Abdelmonaem et al. (2026) studied Solid Ehrlich carcinoma and doxorubicin-induced cardiotoxicity. Arbutin vs. Doxorubicin alone was evaluated. Arbutin effectively reduced tumor weight and volume while attenuating doxorubicin-induced cardiotoxicity by modulating NEK7-dependent inflammasome, SIRT1, caspase-3, and oxidative stress pathways.
Synapse has enriched 10 related papers. Consider them for comparative context: